Eli Lilly will acquire Ventyx Biosciences in a $1.2 billion deal, sending Ventyx shares soaring 56% on the news. UBS initiated coverage on Ventyx with a Buy rating, projecting 45% upside prior to the acquisition announcement. The deal marks a significant premium for the biosciences company. Ventyx was among the day's biggest movers in midday trading alongside Deckers Outdoor, Amgen, and Western Digital. The acquisition talks were first reported by The Wall Street Journal, with the deal valued at over $1 billion before the final $1.2 billion price was confirmed.